Technical Analysis for COLL - Collegium Pharmaceutical, Inc.

Grade Last Price % Change Price Change
A 39.35 0.67% 0.26
COLL closed up 0.67 percent on Monday, March 18, 2024, on 1.47 times normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Doji - Bearish? Reversal 0.00%
New 52 Week High Strength 0.00%
Overbought Stochastic Strength 0.00%
New 52 Week Closing High Bullish 0.67%
Expansion Breakout Bullish Swing Setup 0.67%
Pocket Pivot Bullish Swing Setup 0.67%
Volume Surge Other 0.67%
New 52 Week High Strength 0.67%

   Recent Intraday Alerts

Alert Time
Up 2% about 11 hours ago
60 Minute Opening Range Breakout about 12 hours ago
Rose Above Previous Day's High about 14 hours ago
New 52 Week High about 14 hours ago
Up 1% about 14 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Collegium Pharmaceutical, Inc. Description

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, focuses on developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its lead product candidate is Xtampza, an abuse-deterrent, extended-release, oral formulation of oxycodone, a prescribed opioid medication. The company is also developing COL-172, an abuse-deterrent, extended-release oxymorphone for the treatment of chronic pain; COL-195, an abuse-deterrent, extended-release hydrocodone for the treatment of chronic pain; COL-196, a morphine formulation for the treatment of pain; and COL-171, a proprietary preclinical DETERx extended-release, abuse-deterrent methylphenidate formulation for the treatment of attention deficit hyperactivity disorder. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Canton, Massachusetts.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Disease Pain Organic Compounds Chemical Compounds Euphoriants Opioids Chronic Pain Platform Technology Ethers Attention Deficit Hyperactivity Disorder Morphinans Hyperactivity Disorder Treatment Of Chronic Pain Methylphenidate Phenols Hydrocodone Morphine Oxycodone Oxymorphone Treatment Of Attention Deficit Hyperactivity Disorder

Is COLL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 39.9
52 Week Low 20.835
Average Volume 394,211
200-Day Moving Average 26.49
50-Day Moving Average 34.42
20-Day Moving Average 36.56
10-Day Moving Average 37.75
Average True Range 1.21
RSI (14) 73.19
ADX 34.25
+DI 33.78
-DI 11.33
Chandelier Exit (Long, 3 ATRs) 36.26
Chandelier Exit (Short, 3 ATRs) 34.98
Upper Bollinger Bands 40.57
Lower Bollinger Band 32.55
Percent B (%b) 0.85
BandWidth 21.93
MACD Line 1.39
MACD Signal Line 1.24
MACD Histogram 0.1487
Fundamentals Value
Market Cap 1.28 Billion
Num Shares 32.6 Million
EPS 0.24
Price-to-Earnings (P/E) Ratio 163.96
Price-to-Sales 2.01
Price-to-Book 6.11
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 40.91
Resistance 3 (R3) 40.92 40.41 40.65
Resistance 2 (R2) 40.41 40.01 40.41 40.56
Resistance 1 (R1) 39.88 39.77 39.63 39.87 40.48
Pivot Point 39.37 39.37 39.24 39.37 39.37
Support 1 (S1) 38.84 38.97 38.59 38.83 38.22
Support 2 (S2) 38.33 38.73 38.33 38.14
Support 3 (S3) 37.80 38.33 38.05
Support 4 (S4) 37.79